X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4 targeted small molecule therapeutics to benefit people with rare immune system disorders, today announced that it has agreed to sell an aggregate of 50,925,365 shares …
Trending at Lumira Ventures
Corvia Medical Closed $54 Million Financing to Support Planned Confirmatory Trial of the Corvia® Atrial Shunt
Existing investor syndicate supports atrial shunting as effective therapy for heart failure patients TEWKSBURY, Mass., June 9, 2022 /PRNewswire/ — Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure (HF), today announced the closing of a $54 million equity financing …
Lumira Ventures Builds Upon Presence in Western Canada with Partner Lu Han, Ph.D. Expanding Firm’s Vancouver Office
TORONTO, Ontario, June 14, 2022 — Lumira Ventures, a global healthcare venture capital firm, announced today that Partner Lu Han Ph.D. has relocated to the firm’s office in Vancouver, British Colombia. Dr. Han will expand upon Lumira Ventures’ success in …
Lumira Ventures Announces Appointment of David Novak as Venture Partner
Accomplished Biotechnology Industry Equity Analyst Will Support Firm’s Public Market Investment Initiatives TORONTO, Ontario, June 7, 2022 — Lumira Ventures, a global healthcare venture capital firm, announced today the addition of David Novak to its investment team as a Venture …
HistoSonics Hits Pivotal Clinical Trial Milestone In #HOPE4LIVER Studies
Company Continues to Build as It Prepares for FDA Submission and Clearance of Its Breakthrough Therapy HistoSonics, the developer and manufacturer of a non-invasive platform and novel sonic beam therapy called histotripsy, announced today the fulfillment of patient enrollment required for …
HistoSonics Announces Agreement with GE Healthcare
MINNEAPOLIS, May 23, 2022 — HistoSonics Inc., developer of a completely non-invasive platform using the science of histotripsy, today announced an agreement formalizing ongoing efforts to use GE Healthcare’s LOGIQ E10 Series ultrasound imaging platform to power the real time visualization features of …
XyloCor Therapeutics Presents Preliminary Clinical Data from Phase 1 Portion of the EXACT Phase 1/2 Study of XC001 Novel Gene Therapy for Refractory Angina
Data from the Phase 1 dose-escalation portion of the Phase 1/2 EXACT study demonstrate XC001 was well-tolerated at all dose levels tested; highest dose level evaluated selected for ongoing Phase 2 portion of the study Preliminary efficacy data highlight XC001 …
Congruence Therapeutics Inc. Announces US$50 million Series A Financing to Advance Platform Targeting Diseases of Protein Misfolding
Congruence Therapeutics, a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding, announced today the closing of a US$50 million, tranched, series A financing. The financing was led …
Specific Biologics Closes Seed Financing with Industry Leaders Lumira Ventures and adMare BioInnovations
Specific Biologics Inc. (“Specific”) today announced that it has closed its first institutional financing, led by Lumira Ventures and adMare BioInnovations which have recently established an innovative partnership to build Canadian life sciences companies. Gene editing holds the potential to …
Lumira Co-Leads OncoMyx $50 Million Series B to Advance a Novel Immuno-Oncology Platform that Delivers Multiple Cancer-Killing Payloads
OncoMyx Therapeutics, a privately-held immuno-oncology platform company, today announced the closing of a $50 million Series B financing, co-led by Lumira Ventures and B Capital Group with participation from LYZZ Capital and all Series A investors: Boehringer Ingelheim Venture Fund, …
Deka Biosciences Raises $20 Million in Series A Financing
Maryland-based biotech company Deka Biosciences (“Deka”) today announced that it has successfully closed a USD 20 Million Series A financing with a syndicate of life science investors led by Leaps by Bayer, the impact investment arm of Bayer AG, and new investor …
Antios Therapeutics Raises $75 Million in a Series B-1 Funding to Advance Clinical Programs for HBV
Antios Therapeutics, Inc. (“Antios”), a clinical-stage biopharmaceutical company developing innovative therapies to treat and cure chronic hepatitis B virus (HBV), today announced the successful closing of a $75 million Series B-1 financing. The financing round was co-led by GordonMD Global …
LAVA Medtech Acquisition Corp. Announces Closing of $115 Million Initial Public Offering Including Full Exercise of the Over-Allotment Option
LAVA Medtech Acquisition Corp. (the “Company”) today announced the closing of its initial public offering of 11,500,000 units at a price of $10.00 per unit, including 1,500,000 units pursuant to the full exercise of the underwriters’ over-allotment option. The offering was …
Lumira Ventures Closes on US$255 Million of New Capital to Build Transformative Healthcare Companies
Oversubscribed Lumira Ventures IV to continue successful focus backing biotechnology and medtech companies in Canada and U.S. Companion strategic fund formed in partnership with international pharmaceutical company During the past 18 months Lumira Ventures completed 8 exit transactions and portfolio …
Iterion Therapeutics Secures $17 Million to Advance Development of Tegavivint in Multiple Tumor Settings
Series B financing to support ongoing Phase 1/2a clinical trial of Tegavivint in desmoid tumors and initiation of clinical trials in acute myeloid leukemia, non-small cell lung cancer and pediatric cancers HOUSTON, Feb. 16, 2021 /PRNewswire/ — Iterion Therapeutics, Inc. (“Iterion”), …